Comparison of CalliSpheres^® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial

1Chen C, Qiu H, Yao Y, Zhang Z, Ma C, Ma Y, et al. Comprehensive predictive factors for CalliSpheres^® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol 2021; 45: 101460. doi: 10.1016/j. clinre.2020.05.008 Chen C Qiu H Yao Y Zhang Z Ma C Ma Y et al Comprehensive predictive factors for CalliSpheres^® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients Clin Res Hepatol Gastroenterol 2021 45 101460 doi 10.1016/j.clinre.2020.05.008Open DOISearch in Google Scholar

2Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 2018; 67: 401-21. doi: 10.1002/hep.29487 Roberts LR Sirlin CB Zaiem F Almasri J Prokop LJ Heimbach JK et al Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis Hepatology 2018 67 401 21 doi 10.1002/hep.29487Open DOISearch in Google Scholar

3Della Corte C, Triolo M, Iavarone M, Sangiovanni A. Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver Int 2016; 36: 166-76. doi: 10.1111/liv.12965 Della Corte C Triolo M Iavarone M Sangiovanni A Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives Liver Int 2016 36 166 76 doi 10.1111/liv.12965Open DOISearch in Google Scholar

4Kishore S, Friedman T, Madoff DC. Update on embolization therapies for hepatocellular carcinoma. Curr Oncol Rep 2017; 19: 40. doi: 10.1007/s11912-017-0597-2 Kishore S Friedman T Madoff DC Update on embolization therapies for hepatocellular carcinoma Curr Oncol Rep 2017 19 40 doi 10.1007/s11912-017-0597-2Open DOISearch in Google Scholar

5Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35: 2155-66. doi: 10.1111/liv.12818 Park JW Chen M Colombo M Roberts LR Schwartz M Chen PJ et al Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study Liver Int 2015 35 2155 66 doi 10.1111/liv.12818Open DOISearch in Google Scholar

6de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, et al. Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol 2016; 39: 334-43. doi: 10.1007/s00270-015-1208-y de Baere T Arai Y Lencioni R Geschwind JF Rilling W Salem R et al Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion Cardiovasc Intervent Radiol 2016 39 334 43 doi 10.1007/s00270-015-1208-yOpen DOISearch in Google Scholar

7Sun J, Zhou G, Xie X, Gu W, Huang J, Zhu D, et al. Efficacy and safety of drug-eluting beads transarterial chemoembolization by CalliSpheres^® in 275 hepatocellular carcinoma patients: results from the Chinese CalliSpheres^® Transarterial Chemoembolization in Liver Cancer (CTILC) study. Oncol Res 2020; 28: 75-94. doi: 10.3727/096504019x15662966719585 Sun J Zhou G Xie X Gu W Huang J Zhu D et al Efficacy and safety of drug-eluting beads transarterial chemoembolization by CalliSpheres^® in 275 hepatocellular carcinoma patients: results from the Chinese CalliSpheres^® Transarterial Chemoembolization in Liver Cancer (CTILC) study Oncol Res 2020 28 75 94 doi 10.3727/096504019x15662966719585Open DOISearch in Google Scholar

8Peng Z, Cao G, Hou Q, Li L, Ying S, Sun J, et al. The comprehensive analysis of efficacy and safety of CalliSpheres^® drug-eluting beads transarterial chemoembolization in 367 liver cancer patients: a multiple-center, cohort study. Oncol Res 2020; 28: 249-71. doi: 10.3727/096504019x15766663541105 Peng Z Cao G Hou Q Li L Ying S Sun J et al The comprehensive analysis of efficacy and safety of CalliSpheres^® drug-eluting beads transarterial chemoembolization in 367 liver cancer patients: a multiple-center, cohort study Oncol Res 2020 28 249 71 doi 10.3727/096504019x15766663541105Open DOISearch in Google Scholar

9Shi Q, Liu J, Li T, Zhou C, Wang Y, Huang S, et al. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis. Clin Res Hepatol Gas 2022; 46: 101893. doi: 10.1016/j. clinre.2022.101893 Shi Q Liu J Li T Zhou C Wang Y Huang S et al Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis Clin Res Hepatol Gas 2022 46 101893 doi 10.1016/j.clinre.2022.101893Open DOISearch in Google Scholar

10Wu B, Zhou J, Ling G, Zhu D, Long Q. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol 2018; 16: 69. doi: 10.1186/s12957-018-1368-8 Wu B Zhou J Ling G Zhu D Long Q CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study World J Surg Oncol 2018 16 69 doi 10.1186/s12957-018-1368-8Open DOISearch in Google Scholar

11Ma Y, Zhao C, Zhao H, Li H, Chen C, Xiang H, et al. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres^® microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients. Am J Transl Res 2019; 11: 7456-70. PMID: 31934293 Ma Y Zhao C Zhao H Li H Chen C Xiang H et al Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres^® microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients Am J Transl Res 2019 11 7456 70 PMID: 31934293Search in Google Scholar

12Duan XH, Ju SG, Han XW, Ren JZ, Li FY, Chen PF, et al. Arsenic trioxideeluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients. Eur Rev Med Pharmaco 2020; 24: 1468-80. doi: 10.26355/eurrev_202002_20206 Duan XH Ju SG Han XW Ren JZ Li FY Chen PF et al Arsenic trioxideeluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients Eur Rev Med Pharmaco 2020 24 1468 80 doi 10.26355/eurrev_202002_20206Open DOISearch in Google Scholar

13Xiang H, Long L, Yao Y, Fang Z, Zhang Z, Zhang Y. CalliSpheres drug-eluting bead transcatheter arterial chemoembolization presents with better efficacy and equal safety compared to conventional TACE in treating patients with hepatocellular carcinoma. Technol Cancer Res Treat 2019; 18: 1533033819830751. doi: 10.1177/1533033819830751 Xiang H Long L Yao Y Fang Z Zhang Z Zhang Y CalliSpheres drug-eluting bead transcatheter arterial chemoembolization presents with better efficacy and equal safety compared to conventional TACE in treating patients with hepatocellular carcinoma Technol Cancer Res Treat 2019 18 1533033819830751 doi 10.1177/1533033819830751Open DOISearch in Google Scholar

14Liang B, Xiang H, Ma C, Xiong B, Ma Y, Zhao C, et al. Comparison of chemoembolization with CalliSpheres^® microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study. Cancer Manag Res 2020; 12: 941-56. doi: 10.2147/cmar.S187203 Liang B Xiang H Ma C Xiong B Ma Y Zhao C et al Comparison of chemoembolization with CalliSpheres^® microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study Cancer Manag Res 2020 12 941 56 doi 10.2147/cmar.S187203Open DOISearch in Google Scholar

15Zhang L, Sun JH, Ji JS, Zhong BY, Zhou GH, Song JJ, et al. Imaging changes and clinical complications after drug-eluting bead versus conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: Multicenter study. AJR Am J Roentgenol 2021; 217: 933-43. doi: 10.2214/ajr.20.24708 Zhang L Sun JH Ji JS Zhong BY Zhou GH Song JJ et al Imaging changes and clinical complications after drug-eluting bead versus conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: Multicenter study AJR Am J Roentgenol 2021 217 933 43 doi 10.2214/ajr.20.24708Open DOISearch in Google Scholar

16Zhang S, Huang C, Li Z, Yang Y, Bao T, Chen H, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres beads in rabbit livers. Drug Deliv 2017; 24: 1011-7. doi: 10.1080/10717544.2017.1344336 Zhang S Huang C Li Z Yang Y Bao T Chen H et al Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres beads in rabbit livers Drug Deliv 2017 24 1011 7 doi 10.1080/10717544.2017.1344336Open DOISearch in Google Scholar

17Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art. World J Gastroenterol 2018; 24: 161-9. doi: 10.3748/wjg.v24.i2.161 Facciorusso A Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art World J Gastroenterol 2018 24 161 9 doi 10.3748/wjg.v24.i2.161Open DOISearch in Google Scholar

18Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev 2019; 72: 28-36. doi: 10.1016/j.ctrv.2018.11.002 Raoul JL Forner A Bolondi L Cheung TT Kloeckner R de Baere T Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence Cancer Treat Rev 2019 72 28 36 doi 10.1016/j.ctrv.2018.11.002Open DOISearch in Google Scholar

19Elshaarawy O, Gomaa A, Omar H, Rewisha E, Waked I. Intermediate stage hepatocellular carcinoma: a summary review. J Hepatocell Carcinoma 2019; 6: 105-17. doi: 10.2147/jhc.S168682 Elshaarawy O Gomaa A Omar H Rewisha E Waked I Intermediate stage hepatocellular carcinoma: a summary review J Hepatocell Carcinoma 2019 6 105 17 doi 10.2147/jhc.S168682Open DOISearch in Google Scholar

20Liang B, Makamure J, Shu S, Zhang L, Sun T, Zheng C. Treatment response, survival, and safety of transarterial chemoembolization with CalliSpheres^® microspheres versus conventional transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis. Front Oncol 2021; 11: 576232. doi: 10.3389/fonc.2021.576232 Liang B Makamure J Shu S Zhang L Sun T Zheng C Treatment response, survival, and safety of transarterial chemoembolization with CalliSpheres^® microspheres versus conventional transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis Front Oncol 2021 11 576232 doi 10.3389/fonc.2021.576232Open DOISearch in Google Scholar

21Liu YS, Lin CY, Chuang MT, Lin CY, Tsai YS, Wang CK, et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol 2018; 18: 124. doi: 10.1186/s12876-018-0848-1 Liu YS Lin CY Chuang MT Lin CY Tsai YS Wang CK et al Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma BMC Gastroenterol 2018 18 124 doi 10.1186/s12876-018-0848-1Open DOISearch in Google Scholar

22Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-50. doi: 10.1016/j.jhep.2012.07.017 Song MJ Chun HJ Song DS Kim HY Yoo SH Park CH et al Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma J Hepatol 2012 57 1244 50 doi 10.1016/j.jhep.2012.07.017Open DOISearch in Google Scholar

23Facciorusso A, Mariani L, Sposito C, Spreafico C, Bongini M, Morosi C, et al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gadtroen Hepatol 2016; 31: 645-53. doi: 10.1111/jgh.13147 Facciorusso A Mariani L Sposito C Spreafico C Bongini M Morosi C et al Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma J Gadtroen Hepatol 2016 31 645 53 doi 10.1111/jgh.13147Open DOISearch in Google Scholar

24Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015; 15: 465. doi: 10.1186/s12885-015-1480-x Kloeckner R Weinmann A Prinz F Pinto dos Santos D Ruckes C Dueber C et al Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma BMC Cancer 2015 15 465 doi 10.1186/s12885-015-1480-xOpen DOISearch in Google Scholar

25Ni JY, Xu LF, Wang WD, Sun HL, Chen YT. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2014; 20: 17206-17. doi: 10.3748/wjg.v20.i45.17206 Ni JY Xu LF Wang WD Sun HL Chen YT Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis World J Gastroenterol 2014 20 17206 17 doi 10.3748/wjg.v20.i45.17206Open DOISearch in Google Scholar